Results 21 to 30 of about 4,372,209 (230)

Is There a “Blind Spot” in Point-of-Care Testing for Residual Heparin After Cardiopulmonary Bypass? A Prospective, Observational Cohort Study

Clinical and Applied Thrombosis/Hemostasis, 2020
Identifying the cause of a bleeding complication after cardiac surgery can be crucial. This study sought to clarify whether the application of unprocessed autologous pump blood influences anti-factor Xa activity after cardiac surgery and evaluated 2 ...
Saskia Wand MD, Daniel Heise MD, Nadine Hillmann MD, Christian Bireta MD, Anselm Bräuer MD, Nicolas von Ahsen MD, Michael Quintel MD   +6 more
doaj   +1 more source

Warfarin versus factor Xa inhibitors in the long-term treatment of cerebral venous sinus thrombosis a single-center retrospective analysis

eNeurologicalSci, 2022
Long-term anticoagulation in the treatment of Cerebral Venous Sinus Thrombosis (CVST) has revolved around the use of warfarin. The relatively recent introduction of Direct Oral Anticoagulants (DOACs), such as Factor Xa inhibitors, in treating CVSTs ...
Alexei Christodoulides, Bradley N. Bohnstedt   +1 more
doaj   +1 more source

Factor Xa induces mitogenesis of coronary artery smooth muscle cell via activation of PAR-2 [PDF]

, 2002
Factor Xa-induced stimulation of coronary artery smooth muscle cells (CASMC) was investigated by analyzing [3H]thymidine incorporation, cell proliferation, and ERK-1/2 activation.
황기철
core   +2 more sources

Theoretical Study of Molecular Structure and Physicochemical Properties of Novel Factor Xa Inhibitors and Dual Factor Xa and Factor IIa Inhibitors

Molecules, 2016
The geometries and energies of factor Xa inhibitors edoxaban, eribaxaban, fidexaban, darexaban, letaxaban, and the dual factor Xa and thrombin inhibitors tanogitran and SAR107375 in both the gas-phase and aqueous solution were studied using the Becke3LYP/
Milan Remko, Anna Remková, Ria Broer
doaj   +1 more source

Design and synthesis of novel factor Xa inhibitors.

, 2000
Design and synthesis of novel factor Xa ...
Jian. Cui (7999973)
core   +3 more sources

Direct factor Xa inhibitor in the prevention of thromboembolism [PDF]

, 2018
Venous thromboembolism is the third most common cause of vascular death after myocardial infarction and stroke, and is associated with considerable morbidity and premature mortality. The incidence of the most serious consequence of venous thromboembolism,
Meretskyi, V., Pertsovych, V., Meretska, I., Viktor Meretskyi, Vasyl Pertsovych, Iryna Meretska, Meretska, Iryna, Pertsovych, Vasyl, Meretskyi, Viktor   +8 more
core   +1 more source

Prediction of inhibition constants of (R)-3-amidinophenylalanine inhibitors toward factor Xa by 2D-QSAR model

Vietnam Journal of Science, Technology and Engineering, 2022
A coagulation cascade forms through proteolytic reactions and involves different factors. There are two coagulation pathways, including intrinsic and extrinsic mechanisms, which converge by the formation of factor Xa.
Thi Bich Van Pham, Minh Hao Hoang
doaj   +1 more source

Assessment of anti-factor Xa activity in critically ill COVID-19 patients receiving three different anticoagulation regimens

SAGE Open Medicine, 2021
Introduction: Critically ill COVID-19 patients are at increased risk of thrombosis with an enhanced risk of bleeding. We aimed to explore the role of anti-factor Xa levels in optimizing the high-intensity anticoagulation’s safety and efficacy and finding
Mohammed A Hamad, Shereen A Dasuqi, Aamer Aleem, Rasha A Omran, Rakan M AlQahtani, Fahad A Alhammad, Abdulaziz H Alzeer   +6 more
doaj   +1 more source

The Impact of Continuous Veno-Venous Hemodiafiltration on the Efficacy of Administration of Prophylactic Doses of Enoxaparin: A Prospective Observational Study

Pharmaceuticals, 2023
Background: Critically ill patients frequently require continuous renal replacement therapy (CRRT). During CRRT, particles up to 10 kDa in size, such as enoxaparin, may be removed. The aim of this study was to determine if patients receiving prophylactic
Aleksander Aszkiełowicz, Karol P. Steckiewicz, Michał Okrągły, Magdalena A. Wujtewicz, Radosław Owczuk   +4 more
doaj   +1 more source

Reduced anticoagulation strategy is associated with a lower incidence of intracerebral hemorrhage in COVID-19 patients on extracorporeal membrane oxygenation

Intensive Care Medicine Experimental, 2023
Background Optimal anticoagulation strategies for COVID-19 patients with the acute respiratory distress syndrome (ARDS) on venovenous extracorporeal membrane oxygenation (VV ECMO) remain uncertain.
Daniel A. Hofmaenner, David Furfaro, Lennart C. Wild, Pedro David Wendel-Garcia, Elias Baedorf Kassis, Ameeka Pannu, Tobias Welte, Rolf Erlebach, Klaus Stahl, Edward Wilson Grandin, Christian Putensen, Reto A. Schuepbach, Shahzad Shaefi, Sascha David, Benjamin Seeliger, Christian Bode, for the BonHanZA study group   +16 more
doaj   +1 more source